High Efficacy and Safety of CD38 and BCMA Bispecific CAR-T in Relapsed or Refractory Multiple Myeloma

The authors assessed the efficacy and safety of B cell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.